Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial
| Autor: | Siegfried Seeber, G Stüben, L. Schlenger, Michael Stahl, Jochen Schütte, Volker Budach, D. Greschuchna, M. Stuschke, H Sack, S. Kolks, M R Müller, Wilfried Eberhardt, M Flasshove, Hansjochen Wilke, H. Teschler, Georgios Stamatis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Adolescent medicine.medical_treatment Risk Assessment Small-cell carcinoma Mediastinoscopy surgery combined modality Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols Preoperative Care small-cell lung cancer medicine Humans Longitudinal Studies Neoplasm Metastasis Lung cancer Survival rate Etoposide Aged Neoplasm Staging Radiotherapy medicine.diagnostic_test business.industry neoadjuvant Regular Article Neoplasms Second Primary Perioperative Middle Aged Prognosis medicine.disease Combined Modality Therapy Surgery Survival Rate Radiation therapy Treatment Outcome Thoracotomy Oncology Female business Chemoradiotherapy medicine.drug |
| Zdroj: | British Journal of Cancer |
| Popis: | Following mediastinoscopy, a prognostically orientated multimodality approach was chosen in selected small-cell lung cancer (SCLC) patients with hyperfractionated accelerated chemoradiotherapy (Hf-RTx) and definitive surgery (S). Stage IB/IIA patients had four cycles of cisplatin/etoposide (PE) and surgery. Stage IIB/IIIA patients had three cycles PE followed by one cycle concurrent chemoradiation including Hf-RTx and surgery. Most stage IIIB patients were not planned for surgery and had CTx followed by sequential RTx or one cycle concurrent CTx/RTx. Of 46 consecutive patients (stage IB six, IIA two, IIB/IIIA 22, IIIB 16) 43 (94%) showed an objective response. Twenty-three of patients (72%) planned for inclusion of S were completely resected (R0) (IB 6/6, IIA 2/2, IIB/IIIA 13/22, IIIB 2/2). Overall toxicity was acceptable – one patient died of septicaemia, no perioperative deaths occurred. Median follow-up of patients alive (n = 21) is 52 months (30+ – 75+). Median survival and 5-year survival rate of all patients are 36 months and 46%, in R0 patients 68 months and 63% (R0-IIB/IIIA/IIIB: not yet reached and 67%). This multimodality treatment including surgery proved highly effective with 100% local control and remarkable long-term survival after complete resection, even in locally advanced SCLC stages IIB/IIIA patients. © 1999 Cancer Research Campaign |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|